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Background: The outcome of patients after radiotherapy (RT) for localized prostate cancer in case of
prostate-specific antigen (PSA) progression during primary hormonal therapy (HT) is not well known.
Methods: A group of 27 patients presenting with PSA progression during primary HT for local prostate cancer RT
was identified among patients who were treated in the years 2000–2004 either using external-beam RT (EBRT;
70.2Gy; n=261) or Ir-192 brachytherapy as a boost to EBRT (HDR-BT; 18Gy + 50.4Gy; n=71). The median follow-up
period after RT was 68 months.
Results: Median biochemical recurrence free (BRFS), disease specific (DSS) and overall survival (OS) for patients with
PSA progression during primary HT was found to be only 21, 54 and 53 months, respectively, with a 6-year BRFS,
DSS and OS of 19%, 41% and 26%. There were no significant differences between different RT concepts (6-year OS
of 27% after EBRT and 20% after EBRT with HDR-BT).
Considering all 332 patients in multivariate Cox regression analysis, PSA progression during initial HT, Gleason
score>6 and patient age were found to be predictive for lower OS (p<0.001). The highest hazard ratio resulted for
PSA progression during initial HT (7.2 in comparison to patients without PSA progression during primary HT). PSA
progression and a nadir >0.5 ng/ml during initial HT were both significant risk factors for biochemical recurrence.
Conclusions: An unfavourable prognosis after PSA progression during initial HT needs to be considered in the
decision process before local prostate radiotherapy. Results from other centres are needed to validate our findings.
Keywords: Prostate cancer, Radiotherapy, Brachytherapy, Ir-192, Prostate-specific antigen, Hormone therapyBackground
External beam radiotherapy (EBRT) and temporary
interstitial brachytherapy (HDR-BT) are all well estab-
lished radiotherapy (RT) techniques for a curative treat-
ment of localized prostate cancer [1-7]. The combination
with hormonal therapy (HT) has been shown to be
associated with improved overall survival for high risk
patients after EBRT in several prospective randomized
studies [8-12]. HT is frequently administered before
brachytherapy for downsizing the prostate volume [13].* Correspondence: mpinkawa@ukaachen.de
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reproduction in any medium, provided the orThe optimal sequencing and duration of HT in com-
bination with EBRT is not well known. A longer dur-
ation of HT proved to be associated with an overall
survival benefit for high risk patients in randomized
trials addressing this question [9,10,14]. A difference was
even found for a neoadjuvant HT comparing eight versus
three months [14].
In daily practice, patients sometimes do not receive a
well defined short-term neoadjuvant HT before present-
ing in the radiotherapy department. In some cases, de-
finitive curative treatment is only postponed. Patients
sometimes receive HT until PSA levels rise after an ini-
tial PSA nadir. These patients were in focus of this
analysis.l Ltd. This is an Open Access article distributed under the terms of the Creative
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HDR-BT boost have been included in this evaluation to
verify the results independently in two separate patient
groups with different radiotherapy concepts. Rando-
mized trials comparing these concepts with two different
dose prescriptions have shown improved biochemical
relapse-free survival applying an HDR-BT boost. How-
ever, survival rates were not reported to differ signifi-
cantly [15,16].
Methods
A group of 27 patients presenting with PSA progression
during primary HT for local prostate cancer RT was
identified among patients who were treated in the years
2000–2004 either using external-beam RT (EBRT;
70.2Gy; n=261) or Ir-192 brachytherapy as a boost to
EBRT (HDR-BT; 18Gy + 50.4Gy; n=71). The indication
for a specific treatment was generally based on the
patient’s and/or the referring urologist’s preference. Only
7 patients received a short-term neoadjuvant HT <6
months. The median follow-up period after RT was 68
months.
A bone scan and abdominal computed tomography
scan was required to exclude lymph node or skeletal me-
tastases for high risk patients at the time of the initial
diagnosis.
Treatment
The referring urologist decided about the indication for
HT due to prognostic risk factors or to offer an immedi-
ate treatment before a later decision for a definitive
curative method. As a consequence, several different
agents have been used: luteinizing hormone-releasing
hormone (LHRH) agonists in 10 cases (37%), antiandro-
gens in 3 cases (11%), a combination of LHRH agonists
and antiandrogens in 5 cases (19%) and an orchiectomy
in 9 cases (33%) in the group with PSA progression dur-
ing initial HT.
An Ir-192 stepping source from an afterloader with a
nominal activity of 370 GBq was used for temporary
HDR-BT. All patients received two fractions to deliver
18Gy to the prostate with 7 days between each fraction.
Within three weeks after brachytherapy EBRT started.
Three dimensional treatment plans were calculated
using a four-field box technique with 15MeV photons
and a multi-leaf collimator. The planning target volume
was required to be enclosed by the 90% isodose relative
to the International Commission on Radiation Units and
Measurements reference point with a margin of 1.5cm
in the anterior/lateral and 1cm in the craniocaudal and
dorsal directions to the clinical target volume (prostate
+/− seminal vesicles). The total median dose to the pros-
tate in the reference point was 50.4Gy at 1.8Gy daily
fractions. For EBRT without additional brachytherapy,the same technique was used up to a median dose of
70.2Gy at 1.8Gy fractions.
Follow-up
All patients had a pretreatment PSA measurement. PSA
data since the initial diagnosis were collected retrospect-
ively from the referring urologist, including the start of
HT and PSA nadir value. The PSA levels were usually
obtained every 3 or 4 months in the first 2 years and
every 6 months thereafter. PSA failure (biochemical fail-
ure) was defined according to the RTOG-ASTRO Phoe-
nix consensus [17]: (1) a rise by 2 ng/ml or more above
the nadir PSA; (2) the date of failure determined “at call”
(not backdated). An initiation of hormonal treatment
after RT was additionally counted as biochemical failure.
Patients who died were censored at the time of death
according to their status at that time. Disease specific
mortality was defined as death from prostate cancer
(patients who died with evidence of disease recurrence
without an independent diagnosis responsible for the
patient’s death). Overall mortality was defined as death
from any cause.
Statistical analysis
Statistical analysis was performed using the SPSS 19.0
(SPSS, Chicago, Ill), software. Contingency table analysis
with the chi-square test was performed to compare
treatment groups with respect to categorical variables. A
t-test was used to compare patient age, follow-up peri-
ods and initial PSA values for patients in different
subgroups.
Kaplan-Meier analysis was used to determine bio-
chemical recurrence, disease specific and overall sur-
vival. Comparisons between groups were made using the
log-rank test. Prognostic factors (T stage, Gleason score,
pre-treatment PSA), radiotherapy technique, HT, dur-
ation of initial HT (dichotomized in >6 months = “long-
term”, and ≤6 months = “short-term”), PSA progression
during initial HT (PSA levels reaching a nadir and rising
before beginning of RT) and PSA nadir before RT after
initial HT (last PSA before beginning of RT considered
for analysis) were tested for their significance in a uni-
variate and multivariate Cox regression analysis (p<0.05
is considered significant).
Results
Nearly half of the total patient group (n=149) received
an initial HT before RT with a curative intent, 19%
(n=62) for a time of more than 6 months (median 15
months, range 6–165 months). A PSA progression dur-
ing initial HT was found in 8% (27 patients; 8%, n=22, in
the EBRT and 7%, n=5, in the HDR-BT subgroup).
Baseline patient characteristics for patients presenting
with PSA progression during primary HT in contrast to
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concepts in the years 2000–2004 are presented in
Table 1. Patients with PSA progression during primary
HT are clearly a selection of patients with adverse prog-
nostic factors already at the time of the initial diagnosis.
Median biochemical recurrence free (BRFS), disease
specific (DSS) and overall survival (OS) for patients with
PSA progression during primary HT was found to be
only 21, 54 and 53 months, respectively, with a 6-year
BRFS, DSS and OS of 19%, 41% and 26%. There were no
significant differences between different RT concepts (6-
year OS of 27% after EBRT and 20% after EBRT with
HDR-BT). Metastases were diagnosed in 16 patients,
with the initial location in bones in 11 patients and
lymph nodes in 6 patients.
The outcome after EBRT and HDR-BT was far more
favourable if all 332 patients were considered (6-year
BRFS: 60% vs. 57%; 6-year DFS: 91% vs. 93%; 6-year OS:
77% vs. 78%; median values not reached). HDR-BT
tended to be superior to EBRT alone for low risk
patients considering BRFS (6-year BRFS: 94% vs. 72%;
p=0.08), with excellent DFS rates (6-year DFS: 100% vs.
99%). A lower PSA nadir after initial HT was found to
be predictive for BRFS (6-year BRFS: 89% vs. 50% with a
nadir ≤0.5 ng/ml vs. >0.5 ng/ml; p=0.006). PSA progres-
sion during initial HT was a crucial adverse prognostic
factor (6-year OS with vs. without PSA progression: 26%
vs. 84%; p<0.001; 6-year DFS with vs. without PSA pro-
gression: 41% vs. 94%; p<0.001).Table 1 Baseline patient characteristics
PSA progr
initial HT
patient age/years median (range)
mean±SD
74 (45–81)
follow-up period/months† median
(range) mean±SD
48 (11–113
T stage >2a† 74%
Gleason score >6† 48%
primary PSA /ng/ml† median (range)
mean±SD
16(4–150)
low risk patients*† 7%
intermediate risk patients**† 7%
high risk patients***† 85%
initial HT (before RT)† 100%
initial HT >6months† 78%
HDR-BT 19%
EBRT 81%
* no risk factors: PSA<10ng/ml; Gleason score<7; cT-stage<2b.
** one risk factor: PSA 10-20ng/ml or Gleason score=7 or cT-stage=2b/c.
*** two risk facors or PSA>20ng/ml or Gleason score>7 or cT-stage>2b/c.
†statistically significant difference (p<0.01).
Abbreviations: HDR-BT = high-dose rate brachytherapy; EBRT = external beam radio
hormonal therapy.Only a few factors proved to have a significant impact
in the multivariate analysis (Table 2). The established
factors T stage >2a, Gleason score >6 and PSA >10 ng/ml
were all of prognostic relevance. Only Gleason score
was found to be significantly relevant for (disease spe-
cific and overall) survival in our patient population.
PSA progression and a nadir >0.5 ng/ml during initial
HT were both significant risk factors for biochemical
recurrence. However, additionally to the Gleason score
and patient age, only PSA progression during HT
remained a significant predictor for survival in the multi-
variate analysis. Figures 1 and 2 well demonstrate the
prognostic impact of PSA progression independently for
the patient groups after EBRT alone or EBRT with an add-
itional HDR-BT boost.
Patients with a shorter time to PSA progression after
starting HT were found to have particularly low overall
survival rates (Figure 3; 6-year overall survival of 0% vs.
57% with time to PSA progression ≤9 months vs. >9
months). Median time to PSA progression was 9 months
(in 41% <6 months). Patients with a shorter time to PSA
progression (≤9 months) tended to have more frequently
higher Gleason scores (62% vs. 36% Gleason score >6)
and T stages (85% vs. 64% >2a).
Most of the patients with PSA progression during ini-
tial HT started RT with a PSA level <10 ng/ml (63%).
OS of patients with PSA progression and a PSA level
<10 ng/ml vs. ≥10 ng/ml (last value before starting RT)
did not differ significantly.ession during
(n=27)
Patient population without
PSA progression (n=305)
72±8 71 (52–84) 71±6
) 50±23 69 (2–115) 66±18
25%
19%
31±37 10(1–300) 16±25
37%
28%
35%
40%
13%
22%
78%
therapy; SD = standard deviation; PSA = prostate-specific antigen; HT =
Table 2 Significant factors in multivariate analysis
Hazard
ratio
95% confidence
interval
P-value
Biochemical recurrence free
survival
T stage ≤2a 1.7 1.1-2.5 0.014
PSA <10ng/ml 1.9 1.2-2.8 0.003
no PSA progression vs. PSA pr.
with HT
3.4 1.9-6.0 <0.001
no PSA progression vs. no HT 1.5 1.2-21 0.024
nadir ≤0.5 vs. >0.5 after initial HT 4.7 1.1-19 0.034
Disease specific survival
Gleason score ≤6 4.0 1.8-9.1 0.001
no HT vs. PSA progression with
HT
23 7.3-72 <0.001
no PSA progression vs. PSA pr.
with HT
9.1 3.7-22 <0.001
Overall survival
age <70years 2.6 1.5-4.4 <0.001
Gleason score ≤6 2.2 1.4-3.7 0.002
no HT vs. PSA progression with
HT
5.2 3.6-9.4 <0.001
no PSA progression vs. PSA pr.
with HT
7.2 3.9-14 <0.001
Abbreviations: PSA = prostate-specific antigen; HT = hormonal therapy.
Figure 2 Overall survival after EBRT with additional HDR-BT
boost. (p<0.001 comparing PSA progression during initial HT vs. no
PSA progression; p=0.005 comparing PSA progression vs. no HT in
log-rank test).
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Antiandrogen hormonal therapy is frequently combined
with different RT methods. Treatment concepts are
often based on the results of randomized trials, particu-
larly for high risk patients receiving EBRT as a singleFigure 1 Overall survival after EBRT as single modality. (p<0.001
comparing PSA progression during initial HT vs. no PSA progression/
no HT in log-rank test).modality [9-11]. A longer duration of HT is usually
favoured for high risk patients according to the results
of prospective randomized trials, especially considering
an adjuvant HT. Studies from the EORTC (European
Organization for Research and Treatment of Cancer)
and RTOG (Radiation Therapy Oncology Group) could
demonstrate the survival benefit of the longer HT dur-
ation (three and two years) in comparison to a shorter
duration (four and six months) [9,10]. A secondaryFigure 3 Overall survival, stratified by the time to PSA
progression after starting hormonal therapy. (p=0.01 comparing
time to PSA progression >9 months vs. ≤9 months in log-rank test).
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survival for patients with HT treatment duration of
more than five years (in comparison to one to five or
less than one years) [18].
In contrast to HT, dose escalation studies did not
show an overall survival benefit yet. A meta-analysis of
randomized, controlled trials reported overall survival
rates of 86% for both high-dose and low-dose radiother-
apy [19], so that a relatively low total dose of 70.2Gy for
patients treated with EBRT alone in this study can not
explain a prognostic disadvantage in this respect. Ac-
cordingly - corresponding to the results of this study -
randomized studies comparing a HDR-BT boost to
EBRT in comparison to EBRT alone did not result in an
overall survival benefit [15,16].
Even six months of short-term neoadjuvant HT
proved to be associated with increased overall survival in
locally advanced prostate cancer (TROG, Trans-Tasman
Radiation Oncology Group, 96.01 trial) [20]. A Canadian
multi-center trial comparing three months versus eight
months of neoadjuvant HT in patients with localized
prostate cancer has shown a significant overall survival
benefit for high risk patients [18]. However, a recently
published analysis of this trial found the biochemical re-
sponse to neoadjuvant HT to be the critical determinant
of benefit in the setting of combined therapy. Multivari-
ate analysis identified post-hormone PSA (PSA nadir
before beginning of RT), Gleason score, initial PSA and T-
stage, not HT duration, as independent predictors of bio-
chemical disease free survival [21]. The PSA level after 7
months of HT has also been found to be a strong inde-
pendent predictor of survival in new metastatic prostate
cancer in a Southwest Oncology Group (SWOG) trial
[22]. These results are in accordance with the results of
our study, demonstrating the independent impact of prog-
nostic factors and post-hormone PSA nadir on biochem-
ical disease free survival. An additional independent
prognostic risk factor was found in our patient population,
namely a PSA progression during initial HT.
With a significant impact for biochemical recurrence
free survival in multivariate analysis, the PSA nadir
could probably become significant in multivariate ana-
lysis for disease and overall survival after a longer
follow-up interval. Patients with PSA progression during
initial HT appear to be a selection with extremely ag-
gressive prostate cancer. These cancers have a consider-
able impact on short term survival rates in contrast to
usually expected high disease specific survival rates after
definitive curative RT (99% 5-year DSS for patients with-
out initial HT in this study).
Two possible reasons can be attributed to this un-
favourable prognosis. First, these tumours consist of a
considerable amount of preselected aggressive cells that
are resistant to antiandrogen therapy and apparentlysimultaneously resistant to radiation. Secondly, these
tumours have a high metastatic potential, leading to the
imminent threat to the patient’s life. A particularly un-
favourable prognosis was found for patients with a PSA
progression after only a few months of HT, indicating a
fast resistance to treatment.
A comparable study of patients receiving irradiation
for localized prostate cancer in case of a PSA progres-
sion after initial HT is presently not available in the lit-
erature. The survival rates that were found in our study
after RT are comparable to studies evaluating the out-
come of androgen independent prostate cancer without
any recorded local treatment [23,24]. Svatek et al. [24]
reported a median disease specific and overall survival of
54 months and 51 months, respectively, for a population
of 129 untreated consecutive patients with androgen in-
dependent prostate cancer. These data are well compar-
able to a median disease specific and overall survival of
54 months and 53 months in our study, so that a benefit
of a local RT is not clear in this patient population. The
decision for a local RT should be made considering this
prognosis.
This is a retrospective analysis in a consecutively trea-
ted patient population, so that limitations exist due to a
variety of underlying confounding factors. The generated
hypothesis should be evaluated in other independent
data sets. Imaging studies, like computed tomography of
the abdomen, bone scan or choline-PET [2] might be
useful not only at the time of the initial diagnosis but
also before the decision for local RT even with smaller
PSA levels, taking into account the high metastatic
potential.
Conclusions
PSA progression during initial antiandrogen hormonal
therapy was found to be independently associated with
an unfavorable prognosis after local radiotherapy for
prostate cancer. This outcome needs to be considered in
the decision process before local prostate radiotherapy.
However, results from other centres are needed to valid-
ate our findings.
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